Home > Boards > US Listed > Medical - Drugs > GlaxoSmithKline (GSK)

By late 1998, Dr. Sullivan had produced a

Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
RNsidersbuying Member Profile
 
Followed By 34
Posts 3,046
Boards Moderated 1
Alias Born 07/26/10
160x600 placeholder
GSK Offers Concessions on Pfizer JV to Quell EU Antitrust Fears Dow Jones News - 6/20/2019 6:53:00 AM
Morphic Holding Sets IPO at 5 Million Shares; Sees Pricing at $14-$16 Apiece Dow Jones News - 6/14/2019 8:04:00 AM
Report of Foreign Issuer (6-k) Edgar (US Regulatory) - 6/12/2019 1:32:53 PM
Report of Foreign Issuer (6-k) Edgar (US Regulatory) - 6/7/2019 6:38:58 AM
Nucala (mepolizumab) Gains FDA Approval for Two New Self-Administration Options Business Wire - 6/6/2019 5:15:00 PM
Report of Foreign Issuer (6-k) Edgar (US Regulatory) - 6/4/2019 6:22:29 AM
Report of Foreign Issuer (6-k) Edgar (US Regulatory) - 6/3/2019 11:12:00 AM
Specialized Disclosure Report (sd) Edgar (US Regulatory) - 5/31/2019 2:05:17 PM
Report of Foreign Issuer (6-k) Edgar (US Regulatory) - 5/24/2019 6:27:25 AM
Report of Foreign Issuer (6-k) Edgar (US Regulatory) - 5/20/2019 9:58:51 AM
Thermo Fisher to Buy Ireland API Plant From GlaxoSmithKline Dow Jones News - 5/16/2019 6:40:00 AM
Thermo Fisher Scientific to Acquire Manufacturing Site in Cork, Ireland, from GSK PR Newswire (US) - 5/16/2019 5:00:00 AM
Report of Foreign Issuer (6-k) Edgar (US Regulatory) - 5/13/2019 4:35:04 PM
Report of Foreign Issuer (6-k) Edgar (US Regulatory) - 5/13/2019 4:06:10 PM
Report of Foreign Issuer (6-k) Edgar (US Regulatory) - 5/8/2019 2:03:27 PM
Confidential Treatment Order (ct Order) Edgar (US Regulatory) - 5/2/2019 4:16:42 PM
GlaxoSmithKline, Innoviva Asthma Inhaler Meets Primary Endpoint in Trial Dow Jones News - 5/2/2019 12:59:00 PM
Report of Foreign Issuer (6-k) Edgar (US Regulatory) - 5/2/2019 12:49:25 PM
Report of Foreign Issuer (6-k) Edgar (US Regulatory) - 5/1/2019 1:38:47 PM
Report of Foreign Issuer (6-k) Edgar (US Regulatory) - 5/1/2019 1:19:50 PM
Report of Foreign Issuer (6-k) Edgar (US Regulatory) - 5/1/2019 11:27:14 AM
GlaxoSmithKline Reports Growing Turnover and Profit in 1Q, Beating Market Expectations Dow Jones News - 5/1/2019 7:58:00 AM
Report of Foreign Issuer (6-k) Edgar (US Regulatory) - 4/29/2019 8:28:21 AM
FDA Approves GlaxoSmithKline's Treatment for Pediatric Patients with Lupus Dow Jones News - 4/26/2019 4:31:00 PM
Report of Foreign Issuer (6-k) Edgar (US Regulatory) - 4/26/2019 1:50:27 PM
RNsidersbuying   Monday, 10/20/14 08:30:42 AM
Re: None
Post # of 137 
By late 1998, Dr. Sullivan had produced a vaccine candidate that she and colleagues at the Centers for Disease Control and Prevention in Atlanta tested in monkeys. On July 28, 1999, she received word via an email from the CDC that tests of blood serum samples from vaccinated test monkeys showed immune responses that, she says, “went through the roof.” She wrote “Yahoo!” in the margin of her lab notes, realizing they had broken new scientific ground.

The vaccine was tested in infected macaque monkeys in the most intensive protective environment known to man, called BSL-4 or Biosafety Level-4, at the CDC, and later by Army researchers at Ft. Detrick in Maryland. Unvaccinated monkeys became sick and died within about a week. The four vaccinated monkeys had no detectable virus-something science had never before accomplished.

“These findings demonstrate that it is possible to develop a preventive vaccine against Ebola virus infection in primates,” wrote Drs. Sullivan, Nabel and colleagues in a letter to the journal Nature in Nov. 2000.


http://online.wsj.com/articles/ebola-vaccine-push-ramps-up-1413762856

Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist